{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Waliany S"],"funding":["NCI NIH HHS"],"pubmed_abstract":["<h4>Purpose</h4>Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRIs) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRIs.<h4>Experimental design</h4>We established 'RETgistry,' a global consortium of patients with advanced RET-altered solid tumors who received SRIs and underwent post-progression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with Kaplan-Meier method.<h4>Results</h4"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12912800"],"repository":["biostudies-literature"],"pubmed_title":["Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium."],"pmcid":["PMC12912800"],"funding_grant_id":["P30 CA008748","R01 CA251591","P50 CA265826","R01 CA273224","R01 CA164273","R01 CA226864"],"pubmed_authors":["Smith KER","Solomon BJ","Patel SA","Weiler D","Sun L","Yeap BY","Mansfield AS","Nagasaka M","Lee DH","Falcon C","Patil T","Gainor JF","Rotow JK","Fruh M","Gadgeel S","Wirth LJ","Lin JJ","Liu SV","Tan DSW","Do A","Weber UM","Cooper AJ","Riess JW","Uy NF","Gautschi O","Waliany S","Feng J","Pall G","Baik CS","Drilon A","Cheung KSY","Lai GGY","Loong HHF","Patel JD","Pennell NA","Leighl NB","Ou SI","Kim TM"],"additional_accession":[]},"is_claimable":false,"name":"Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.","description":"<h4>Purpose</h4>Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRIs) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRIs.<h4>Experimental design</h4>We established 'RETgistry,' a global consortium of patients with advanced RET-altered solid tumors who received SRIs and underwent post-progression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with Kaplan-Meier method.<h4>Results</h4","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-16T00:32:47.819Z","creation":"2026-07-09T13:09:57.242Z"},"accession":"S-EPMC12912800","cross_references":{"pubmed":["41537704"],"doi":["10.1158/1078-0432.ccr-25-4382","10.1158/1078-0432.CCR-25-4382"]}}